GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
2 other identifiers
observational
15,729
16 countries
16
Brief Summary
Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2009
16 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 24, 2009
CompletedFirst Submitted
Initial submission to the registry
May 26, 2009
CompletedFirst Posted
Study publicly available on registry
May 27, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2010
CompletedJune 6, 2023
June 1, 2023
1.8 years
May 26, 2009
June 5, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI)
During observation period of three months
Study Arms (1)
Group 1
Interventions
Eligibility Criteria
* Patients with untreated or pretreated diabetes mellitus type 2 * No Glucobay® intake within the last 3 months before documentation of initial visit * Exclusion Criteria: contraindication stated in the local Glucobay® product information; warnings and precautions must be considered.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayerlead
Study Sites (16)
Unknown Facility
Multiple Locations, Algeria
Unknown Facility
Multiple Locations, Bosnia and Herzegovina
Unknown Facility
Multiple Locations, Cambodia
Unknown Facility
Multiple Locations, China
Unknown Facility
Multiple Locations, Hong Kong
Unknown Facility
Multiple Locations, India
Unknown Facility
Multiple Locations, Indonesia
Unknown Facility
Multiple Locations, Malaysia
Unknown Facility
Multiple Locations, Moldova
Unknown Facility
Multiple Locations, Pakistan
Unknown Facility
Multiple Locations, Philippines
Unknown Facility
Multiple Locations, Russia
Unknown Facility
Multiple Locations, Singapore
Unknown Facility
Multiple Locations, South Korea
Unknown Facility
Multiple Locations, Thailand
Unknown Facility
Multiple Locations, Vietnam
Related Publications (1)
Zhang W, Kim D, Philip E, Miyan Z, Barykina I, Schmidt B, Stein H; Gluco VIP study. A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study. Clin Drug Investig. 2013 Apr;33(4):263-74. doi: 10.1007/s40261-013-0063-3.
PMID: 23435929RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bayer Study Director
Bayer
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 26, 2009
First Posted
May 27, 2009
Study Start
March 24, 2009
Primary Completion
December 31, 2010
Study Completion
December 31, 2010
Last Updated
June 6, 2023
Record last verified: 2023-06